- Home
- BRNS vs OKUR Comparison
BRNS vs OKUR Comparison
Compare BRNS & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- OKUR
- Stock Information
- Founded
- BRNS 2016
- OKUR 2011
- Country
- BRNS United Kingdom
- OKUR United States
- Employees
- BRNS N/A
- OKUR N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- OKUR
- Sector
- BRNS Health Care
- OKUR
- Exchange
- BRNS Nasdaq
- OKUR NYSE
- Market Cap
- BRNS 42.8M
- OKUR 34.9M
- IPO Year
- BRNS 2021
- OKUR N/A
- Fundamental
- Price
- BRNS $1.44
- OKUR $2.28
- Analyst Decision
- BRNS Strong Buy
- OKUR Strong Buy
- Analyst Count
- BRNS 1
- OKUR 4
- Target Price
- BRNS $3.00
- OKUR $32.25
- AVG Volume (30 Days)
- BRNS 3.8M
- OKUR 73.0K
- Earning Date
- BRNS 08-11-2025
- OKUR 08-14-2025
- Dividend Yield
- BRNS N/A
- OKUR N/A
- EPS Growth
- BRNS N/A
- OKUR N/A
- EPS
- BRNS N/A
- OKUR N/A
- Revenue
- BRNS $14,969,000.00
- OKUR N/A
- Revenue This Year
- BRNS N/A
- OKUR N/A
- Revenue Next Year
- BRNS N/A
- OKUR N/A
- P/E Ratio
- BRNS N/A
- OKUR N/A
- Revenue Growth
- BRNS 4381.74
- OKUR N/A
- 52 Week Low
- BRNS $0.64
- OKUR $1.70
- 52 Week High
- BRNS $2.92
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- BRNS 53.79
- OKUR N/A
- Support Level
- BRNS $1.44
- OKUR N/A
- Resistance Level
- BRNS $2.01
- OKUR N/A
- Average True Range (ATR)
- BRNS 0.39
- OKUR 0.00
- MACD
- BRNS -0.00
- OKUR 0.00
- Stochastic Oscillator
- BRNS 24.49
- OKUR 0.00
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.